在体外高含量查显示miR-429作为光受体退化中的保护分子
Georgios Petrogiannakis1,2, Irene Guadagnino1, Santiago Negueruela1
1Telethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli, Italy.
Molecular therapy. Nucleic acids
|January 29, 2025
概括
微RNAs (miRNAs) 在治疗遗传性视网膜疾病 (IRDs) 中表现有前途. 一项研究发现,在IRD小鼠模型中,miR-429保护光受体细胞和降低退化,提供了潜在的突变独立疗法.
科学领域:
- 眼科医生 眼科 眼科
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 遗传性视网膜疾病 (IRD) 是由于光受体退化而导致渐进的视力丧失的原因.
- 微RNAs (miRNAs) 调节基因表达,对视网膜功能和疾病至关重要.
- IRDs的遗传异质性为开发向治疗提出了挑战.
研究的目的:
- 查具有对光受体退化有保护作用的微RNA (miRNA).
- 在遗传性视网膜疾病模型中评估已识别的miRNAs的治疗潜力.
- 验证高含量成像 (HCI) 试验,以发现IRDs的新疗法策略.
主要方法:
- 在光应激光受体类细胞 (661W) 中对超过1200个小RNA进行高含量成像 (HCI) 选.
- 在体外验证高性能miRNAs.
- 在Rho P23H/+ IRD小鼠模型中,阿诺相关的病毒载体介导的miR-429的亚内传递.
主要成果:
- miR-429在体外显示出最强的细胞保护作用.
- 在IRD小鼠模型中,miR-429的亚视网膜输送保留了电生理反应.
- 在小鼠模型中,miR-429治疗导致视网膜炎症过程减少.
结论:
- 开发的HCI测定是一种可靠的方法,用于识别突变独立IRD疗法的候选分子.
- miR-429显示出作为IRDs中的光受体退化治疗剂的显著潜力.
- 这项研究强调了miR-429作为继承性视网膜疾病的有前途的治疗点.
相关概念视频
02:28Leaky Scanning
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R stands for...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...